ClinicalTrials.gg

Program

atumelnant

Also written as “Atumelnant”, “atumelnant (CRN04894)” and “CRN04894 Oral Solution”.

Its studies are mostly in Adrenal Hyperplasia, Congenital · Cushing Syndrome, led by Vertex Pharmaceuticals.

Furthest: phase 3, since Aug 20, 20258 company-led studies, 3 open or runningNext primary completion: May 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vertex Pharmaceuticals83 open or runningphase 3since Aug 20, 2025Mar 27, 2023May 2027phase 3 · NCT07144163

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 27, 2023First study: phase 2 study in Cushing SyndromeFirst studyNCT05804669 · 19 enrolled · United States
  2. Jun 8, 2023Phase 2 study in Adrenal Hyperplasia, CongenitalNCT05907291 · 38 enrolled · United States, Argentina, Brazil and more
  3. Sep 11, 2023Phase 1 study in Healthy VolunteersNCT06048887 · 88 enrolled · United States
  4. Nov 27, 2024Phase 2 study in Adrenal Hyperplasia, CongenitalNCT06712823 · 200 planned · United States, Argentina, Brazil and more
  5. Aug 20, 20252 phase 3 studies in Adrenal Hyperplasia, CongenitalNCT07144163, NCT07159841
  6. Oct 22, 2025Phase 1 study in Healthy VolunteersNCT07221084 · 21 enrolled · United States
  7. Apr 29, 2026Phase 1 study in Healthy VolunteersNCT07570082 · 46 enrolled · United States

Ahead

  1. May 2027Primary completion: phase 3 study in Adrenal Hyperplasia, CongenitalNCT07144163
  2. Jul 2029Primary completion: phase 2 study in Adrenal Hyperplasia, CongenitalNCT06712823
  3. Mar 2030Primary completion: phase 3 study in Adrenal Hyperplasia, CongenitalNCT07159841

TargetBeta

MC2R →POMC →read by rule
“An orally bioavailable nonpeptide antagonist of the adrenocorticotropic hormone (ACTH) receptor (ACTHR; melanocortin receptor 2; MC2R), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
OMS1620ruleomass-therapeutics-australia-proprietary-ltdphase 11

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07570082Healthy Volunteers · United States1CompletedJun 30, 202646
NCT07221084Healthy Volunteers · United States1CompletedFeb 7, 202621
NCT07159841Adrenal Hyperplasia, Congenital · United States, Argentina, Australia and more3RecruitingMar 2030153
NCT07144163Adrenal Hyperplasia, Congenital · United States, Argentina, Australia and more3RecruitingMay 2027150
NCT06712823Adrenal Hyperplasia, Congenital · United States, Argentina, Brazil and more2RecruitingJul 2029200
NCT06048887Healthy Volunteers · United States1CompletedApr 11, 202288
NCT05907291Adrenal Hyperplasia, Congenital · United States, Argentina, Brazil and more2CompletedAug 22, 202538
NCT05804669Cushing Syndrome · United States2CompletedAug 25, 202619

How it is read

Names in the registry

  • “Atumelnant”, 4 entries
  • “atumelnant (CRN04894)”, 2 entries
  • “atumelnant”, 1 entry
  • “CRN04894 Oral Solution”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.